1800 244 735

Helpline (02) 9874 9777

Largest creatine clinical trial for Huntington's disease halted after 'futility' analysis

CREST-E, the largest clinical trial of the dietary supplement creatine, has been terminated early because an early analysis of the results to date showed there was no realistic chance it could show positive results. This provides compelling evidence that creatine doesn’t slow down progression in Huntington’s disease patients.

What is creatine, why are we testing it in HD?

One of the many effects of the Huntington’s disease genetic mutation is that our cells become slightly less efficient at making and using energy. Creatine is a dietary supplement, widely used by bodybuilders, that can acts as a sort of bank to store extra high-energy chemical bonds cells need to make energy. Cells don’t actually burn creatine for energy but they use it as a place to store their extra energy for times of high demand.

Studies in HD animal models had suggested the potential for creatine to be beneficial in Huntington’s disease, but previous clinical trials in HD patients have been disappointing.

What is the CREST-E trial?

Coordinated by the Huntington Study Group, CREST-E aimed to build on previous trials of creatine, to provide definitive evidence either way about whether creatine slows progression in Huntington’s disease.

Not only was CREST-E the largest ever trial of creatine, enrolling 551 volunteers for three years each; it also employed the highest dose of creatine – up to 40 grams per day.

What does it mean to halt a trial for ‘futility’?

Many clinical trials are designed with so-called ‘interim analysis’ points. These enable the researchers to study the results to date, to see whether the therapy being studied is performing unexpectedly well or unexpectedly badly. This allows informed decisions to be made about whether the trial should be continued or abandoned.

A futility analysis is designed to ask, part-way through a trial, whether the chance of a positive outcome is so slim that there is little point continuing with the trial.

Unfortunately, the futility analysis for CREST-E showed just that. There was no real chance creatine could show clinical benefit, so the trial was stopped early.

Is this the end of the road for creatine?

While disappointing, CREST-E provides very useful information to help guide decisions for HD family members and their clinicians. CREST-E was well-designed and well run, but unfortunately showed quite convincingly that high-dose creatine doesn’t slow progression of Huntington’s disease.

Another study called PRECREST studied creatine in volunteers with the HD mutation but no symptoms. The results of PRECREST suggested some possible benefit for brain changes seen on MRI scans in HD. But the halting of CREST-E, which measured the real clinical effects of creatine, makes it hard to believe that the PRECREST findings would translate into delaying HD onset.

Now what?

While we’d love to be reporting the first successful clinical trial for slowing HD, it’s undoubtedly true that every trial will fail, until one doesn’t.

The important thing right now is to learn from ‘negative’ outcomes like this. Studies like CREST-E have helped us, as a community, to get really good at designing, enrolling and running clinical trials, and understanding why particular treatments don’t work. Now we have the result of CREST-E, all that energy, enthusiasm and experience can be directed into testing other experimental treatments with a higher chance of success. One very solid benefit is that hundreds of volunteers are now freed up to sign up for other clinical trials enrolling now or in the near future.

Thankfully, science never stops! Huntington’s disease researchers and drug-hunters across the globe have been hard at work studying the effects of the HD mutation and coming up with treatments designed with HD specifically in mind. This is in contrast to substances like creatine, which were thought to be beneficial for the brain in a much more general way.

As we recently reported from the European Huntington’s Disease Network meeting, no fewer than five new HD clinical trials are either underway already or enrolling soon. The biggest are Amaryllis, Legato-HD and Pride-HD, enrolling now or soon in North America and Europe. Your local HD clinic or Center of Excellence will have information on which trials you may be eligible for, and how to get involved.

Share on facebook
Share on twitter
Share on pinterest
Share on email

Latest Research Articles

Scientists identify precisely how pridopidine works in models of Huntington’s disease

Published date: 12 June, 2021

Pridopidine is a drug developed to treat Huntington’s disease (HD) and now scientists have a clearer understanding of how it works in the body and brain. In a series of academic papers, researchers figured out that pridopidine is working by targeting a particular receptor protein called S1R. With this new understanding, the researchers believe pridopidine ... Read more

Huntington's disease therapeutics conference 2021 – Day 3

Published date: 29 April, 2021

We are back for the last day of the virtual 2021 CHDI Therapeutics conference. This article summarises our live Twitter updates on the exciting science being presented, which you can find with the hashtag #HDTC2021. The final session of the conference will provide the latest news on more Huntington’s disease clinical programs. A new way ... Read more

Huntington's disease therapeutics conference 2021 – Day 2

Published date: 28 April, 2021

We are back with Day 2 of the virtual 2021 CHDI Therapeutics conference. This article summarises our live Twitter updates on the exciting science being presented, which you can continue to follow with the hashtag #HDTC2021. The morning session focussed on promising HD therapeutics that are in preclinical development and the afternoon session covered different ... Read more

Huntington’s disease therapeutics conference 2021 – Day 1

Published date: 28 April, 2021

The CHDI Therapeutics Conference 2021 kicked off today. This article summarizes our live Twitter updates on the exciting science being presented, which you can continue to follow with the hashtag #HDTC2021. The morning of Day 1 focused on clinical trial updates, while the afternoon explored genetic modifiers of HD and how they might be harnessed ... Read more

Huntington’s disease clinical trial round up

Published date: 26 April, 2021

It seems like the HD community has been inundated with updates from different companies and clinical trials recently. The news is far from complete doom and gloom; although there have been some real disappointments from some of the frontrunner trials, there are also positive updates from many different companies and lots of reasons for us ... Read more

Good news from uniQure: gene therapy trial on track, and promising data in animals

Published date: 15 April, 2021

Two recent press releases from uniQure provide welcome good news: the first ever HD gene therapy, known as AMT-130, has been administered via brain surgery to a small set of participants in an early safety trial. At the same time, uniQure has published findings in HD animal models that increase confidence in the drug’s ability ... Read more